SCHEMBL13655257

SCHEMBL13655257

Nc1ncc(-c2cccc(NC(=O)c3cccs3)c2)[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
SCN4A P35499 1/20 0.58
SCN9A Q15858 1/20 0.58
SCN3A Q9NY46 1/20 0.58
RAB9A P51151 3/20 0.56
NPC1 O15118 2/20 0.56
CLK1 P49759 1/20 0.56
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
KDM4E B2RXH2 3/20 0.53
LMNA P02545 3/20 0.53
HTT P42858 3/20 0.53
HPGD P15428 3/20 0.52
KCNK3 O14649 1/20 0.51
KCNK9 Q9NPC2 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
ALDH1A1 P00352 2/20 0.50
GLA P06280 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20501030 0.81 SCN9A (0.61) MAPTSCN4ASCN9ASCN3APDGFRB
SCHEMBL28368753 0.80 SCN9A (0.60) MAPTSMN1; SMN2SCN4ASCN9ASCN3A
SCHEMBL20501076 0.78 SCN9A (0.61) MAPTSCN4ASCN9ASCN3ARAB9A
SCHEMBL13655269 0.78 SCN9A (0.59) SCN4ASCN9ASCN3AMEN1KMT2A
SCHEMBL13655093 0.77 SCN4A (0.58) MAPTSMN1; SMN2SCN4ASCN9ASCN3A
SCHEMBL20501157 0.77 SCN9A (0.57) SCN4ASCN9ASCN3A
SCHEMBL20501163 0.77 HTR2C (0.50) SMN1; SMN2SCN4ASCN9ASCN3ARAB9A
SCHEMBL29684351 0.76 KCNK3 (0.74) MAPTSMN1; SMN2RAB9ANPC1CLK1
SCHEMBL13664650 0.76 SCN9A (0.64) MAPTSMN1; SMN2SCN4ASCN9ASCN3A
SCHEMBL23011772 0.75 KCNK3 (0.82) MAPTSMN1; SMN2RAB9ANPC1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975857-B2 Inhibition of bacterial biofilms with imidazole-phenyl derivatives NORTH CAROLINA STATE UNIVERSITY (US) 2018-05-22 US disclosed
US-9975857-B2 Inhibition of bacterial biofilms with imidazole-phenyl derivatives NORTH CAROLINA STATE UNIVERSITY (US) 2018-05-22 US disclosed
US-20150183746-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES UNIV NORTH CAROLINA STATE (US) 2015-07-02 US disclosed
US-20150183746-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES UNIV NORTH CAROLINA STATE (US) 2015-07-02 US disclosed
US-9005643-B2 Inhibition of bacterial biofilms with imidazole-phenyl derivatives NORTH CAROLINA STATE UNIVERSITY (US) 2015-04-14 US disclosed
US-9005643-B2 Inhibition of bacterial biofilms with imidazole-phenyl derivatives NORTH CAROLINA STATE UNIVERSITY (US) 2015-04-14 US disclosed
US-20090270475-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES NORTH CAROLINA STATE UNIVERSITY (US) 2009-10-29 US disclosed
US-20090270475-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES NORTH CAROLINA STATE UNIVERSITY (US) 2009-10-29 US disclosed
WO-2009123753-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES NORTH CAROLINA STATE UNIVERSITY (US) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270475-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES TFPI, O60361, PGLS MAPT 2809/4885SMN1; SMN2 4885/4885SCN4A 4192/4885
US-20150183746-A1 INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-PHENYL DERIVATIVES TFPI, O60361, PGLS MAPT 2809/4885SMN1; SMN2 4885/4885SCN4A 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.